title: Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP).
abstract: YHK has antioxidant properties, has a hypoglycemic effect, and may reduce plasma lipid levels. In this study, we examined the hepatic expression of PPAR-alpha and -gamma and MTP in ob/ob mice receiving or not receiving YHK. Ob/ob mice were assigned to receive oral YHK (20 mg/kg/day) fed solution (methionine/choline-deficient [MCD] diet+YHK group) or vehicle (MCD group) by gavage for 4 weeks. Liver fragments were collected for histologic examination and mRNA isolation. PPAR-alpha and -gamma and MTP gene expression was examined by RT-qPCR. YHK treatment was associated with NASH prevention, weight loss, and reduction of visceral fat and of serum concentrations of aminotransferases in comparison to the MCD group. YHK promoted an increment in PPAR-alpha and MTP and a decrement in PPAR-gamma mRNA contents. These findings suggest that modulation of PPAR-alpha and -gamma and MTP RNA expression may be implicated in the protective effect of YHK in experimental NASH, limiting hepatocyte lipid accumulation.
authors: University of Sao Paulo School of Medicine, Department of Gastroenterology (LIM-07), Sao Paulo, SP, Brazil. jstefano@usp.br
authors: José Tadeu
authors: JT
authors: Stefano
authors: Claudia Pinto Marques Souza
authors: CP
authors: de Oliveira
authors: Maria Lúcia
authors: ML
authors: Corrêa-Giannella
authors: Vicência Mara Rodrigues
authors: VM
authors: de Lima
authors: Sandra Valéria
authors: SV
authors: de Sá
authors: Ellen Pierre
authors: EP
authors: de Oliveira
authors: Evandro Sobroza
authors: ES
authors: de Mello
authors: Daniel
authors: D
authors: Giannella-Neto
authors: Venâncio Avancini Ferreira
authors: VA
authors: Alves
authors: Flair José
authors: FJ
authors: Carrilho
mesh_terms: D000818:Animals; D002352:Carrier Proteins / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics*; D004195:Disease Models, Animal; D018450:Disease Progression; D005234:Fatty Liver / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects / Q000235:genetics*; D022781:Hepatocytes / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008820:Mice, Obese; D008862:Microsomes, Liver; D047493:PPAR alpha / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics*; D047495:PPAR gamma / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics*; D008517:Phytotherapy / Q000379:methods; D028321:Plant Preparations / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome
chemical_list: D002352:Carrier Proteins; D047493:PPAR alpha; D047495:PPAR gamma; D028321:Plant Preparations; D012333:RNA, Messenger; C516652:YHK herbal compound; C106092:microsomal triglyceride transfer protein